Harvard Bioscience (HBIO) Q2 2026 Earnings Call Transcript
Harvard Bioscience (HBIO) reported Q2 2026 revenue of $22.7M, up 11%, and adjusted EBITDA of $1.7M, up 11%. Full-year revenue guidance was raised to 3-5% growth, but gross margin guidance was lowered to 57-59% due to product and geographic mix shifts. The company expects $3M in cost savings from Project Viking in 2027. Americas and APAC regions showed strong growth, while Europe grew modestly. Adjusted EPS was -$0.14, and Q3 revenue guidance is $21.0M-$22.6M.
How this was made
The 30-second read
Why it matters
Traders can update models for HBIO using the raised FY revenue growth range, the lowered FY gross margin range, and the Q3 revenue and adjusted EBITDA guidance ranges. The key tension is growth acceleration versus margin compression from mix and geography, partially offset by planned cost savings beginning in 2027.
Market read
HBIO’s updated guidance is the actionable element: revenue growth expectations improve, but gross margin expectations are reduced, with cash flow pressure tied to inventory and financing costs.
What to watch
Inventory builds and higher interest costs from debt refinancing reduced operating cash flow, which could matter more than the headline revenue growth for near-term risk pricing.
Background
This is a transcript-style summary of Harvard Bioscience’s Q2 2026 earnings call, including management’s updated FY and Q3 guidance and commentary on Project Viking manufacturing consolidation.
Ticker impact
Harvard Bioscience reported Q2 revenue of $22.7M, raised full-year revenue guidance to 3% to 5%, and revised gross margin guidance to 57% to 59%.
Near-term trading likely hinges on whether investors focus more on raised revenue guidance or the lowered gross margin outlook.
The article provides specific, decision-relevant forward guidance (revenue up, gross margin down) plus Q3 revenue and EBITDA ranges, which can reprice expectations for both top-line momentum and margin trajectory.
Market effects
Signals demand strength in CRO-linked telemetry and China localization, but highlights margin sensitivity to mix shifts toward lower-margin CMT and China sales.
APAC and China growth are emphasized (APAC +24%, China +29%), which may influence regional biotech tool demand expectations.
Could modestly affect sentiment around life-science tools suppliers’ ability to scale localized manufacturing while protecting gross margins.
Counterpoint
The margin guide cut may be temporary, since management attributes it to mix and points to Project Viking cost savings starting in 2027.
Key entities
- companyHarvard Bioscience, Inc.
Subject of the earnings call, providing Q2 results and updated FY/Q3 guidance, including Project Viking cost savings and margin outlook changes.
- executiveJohn Duke
CEO who discussed product adoption and translational research value proposition.
- executiveMark Frost
CFO who explained the adjusted gross margin decline and cash flow drivers.
